Review



primary antibodies against l-pgds  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Santa Cruz Biotechnology primary antibodies against l-pgds
    ( A ) <t>L-PGDS</t> expression by WB from samples collected from MCA areas of sham-operated mice or ischemic areas at 1, 3, 5, and 7 days post-stroke. ( B , C ) WB analysis at 7 days post-stroke. L-PGDS expression levels were significantly higher in ischemic areas compared to the contralateral side of nonischemic areas. ( D – G ) Immunohistochemistry for L-PGDS and GFAP. L-PGDS was strongly detected in the leptomeninges of ischemic areas (L-PGDS [( E – G ): red]); GFAP [( E – G ): green]; DAPI [( E – G ): blue]). ( H – K ) Immunohistochemistry for L-PGDS and PDGFRβ. L-PGDS was co-expressed in PDGFRβ + pericytes in the leptomeninges of ischemic areas (( I – K ), arrows) (L-PGDS [( I , J ): red]; PDGFRβ [( I , K ): green]; DAPI [( I – K ): blue]). ( L – N ) RT-qPCR analysis. L-PGDS levels were significantly higher in brain pericytes treated with supernatant from ischemic areas ( M , N ) than in untreated pericytes (control) ( L , N ). Scale bars: ( E – G ) 100 µm; ( I ) 20 µm. * p < 0.05 between the contralateral side of nonischemic areas and ischemic areas, n = 3 for each area ( C ). * p < 0.05 between the control and supernatant–treated group, n = 3 for each group ( N ). Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; GFAP, glial fibrillary acidic protein; L-PGDS, lipocalin-type prostaglandin D synthase; MCA, middle cerebral artery; PDGFRβ, platelet-derived growth factor receptor-β; RT-qPCR, quantitative reverse transcription-polymerase chain reaction; WB, Western blot.
    Primary Antibodies Against L Pgds, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibodies+against+l-pgds/primary+antibodies+against+l+pgds/pmc11505914-66-6-11
    Average 90 stars, based on 1 article reviews
    primary antibodies against l-pgds - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "L-PGDS–PGD2–DP1 Axis Regulates Phagocytosis by CD36 + MGs/MΦs That Are Exclusively Present Within Ischemic Areas After Stroke"

    Article Title: L-PGDS–PGD2–DP1 Axis Regulates Phagocytosis by CD36 + MGs/MΦs That Are Exclusively Present Within Ischemic Areas After Stroke

    Journal: Cells

    doi: 10.3390/cells13201737

    ( A ) L-PGDS expression by WB from samples collected from MCA areas of sham-operated mice or ischemic areas at 1, 3, 5, and 7 days post-stroke. ( B , C ) WB analysis at 7 days post-stroke. L-PGDS expression levels were significantly higher in ischemic areas compared to the contralateral side of nonischemic areas. ( D – G ) Immunohistochemistry for L-PGDS and GFAP. L-PGDS was strongly detected in the leptomeninges of ischemic areas (L-PGDS [( E – G ): red]); GFAP [( E – G ): green]; DAPI [( E – G ): blue]). ( H – K ) Immunohistochemistry for L-PGDS and PDGFRβ. L-PGDS was co-expressed in PDGFRβ + pericytes in the leptomeninges of ischemic areas (( I – K ), arrows) (L-PGDS [( I , J ): red]; PDGFRβ [( I , K ): green]; DAPI [( I – K ): blue]). ( L – N ) RT-qPCR analysis. L-PGDS levels were significantly higher in brain pericytes treated with supernatant from ischemic areas ( M , N ) than in untreated pericytes (control) ( L , N ). Scale bars: ( E – G ) 100 µm; ( I ) 20 µm. * p < 0.05 between the contralateral side of nonischemic areas and ischemic areas, n = 3 for each area ( C ). * p < 0.05 between the control and supernatant–treated group, n = 3 for each group ( N ). Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; GFAP, glial fibrillary acidic protein; L-PGDS, lipocalin-type prostaglandin D synthase; MCA, middle cerebral artery; PDGFRβ, platelet-derived growth factor receptor-β; RT-qPCR, quantitative reverse transcription-polymerase chain reaction; WB, Western blot.
    Figure Legend Snippet: ( A ) L-PGDS expression by WB from samples collected from MCA areas of sham-operated mice or ischemic areas at 1, 3, 5, and 7 days post-stroke. ( B , C ) WB analysis at 7 days post-stroke. L-PGDS expression levels were significantly higher in ischemic areas compared to the contralateral side of nonischemic areas. ( D – G ) Immunohistochemistry for L-PGDS and GFAP. L-PGDS was strongly detected in the leptomeninges of ischemic areas (L-PGDS [( E – G ): red]); GFAP [( E – G ): green]; DAPI [( E – G ): blue]). ( H – K ) Immunohistochemistry for L-PGDS and PDGFRβ. L-PGDS was co-expressed in PDGFRβ + pericytes in the leptomeninges of ischemic areas (( I – K ), arrows) (L-PGDS [( I , J ): red]; PDGFRβ [( I , K ): green]; DAPI [( I – K ): blue]). ( L – N ) RT-qPCR analysis. L-PGDS levels were significantly higher in brain pericytes treated with supernatant from ischemic areas ( M , N ) than in untreated pericytes (control) ( L , N ). Scale bars: ( E – G ) 100 µm; ( I ) 20 µm. * p < 0.05 between the contralateral side of nonischemic areas and ischemic areas, n = 3 for each area ( C ). * p < 0.05 between the control and supernatant–treated group, n = 3 for each group ( N ). Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; GFAP, glial fibrillary acidic protein; L-PGDS, lipocalin-type prostaglandin D synthase; MCA, middle cerebral artery; PDGFRβ, platelet-derived growth factor receptor-β; RT-qPCR, quantitative reverse transcription-polymerase chain reaction; WB, Western blot.

    Techniques Used: Expressing, Immunohistochemistry, Quantitative RT-PCR, Control, Derivative Assay, Reverse Transcription, Polymerase Chain Reaction, Western Blot

    Related Articles

    Incubation:

    Article Title: L-PGDS–PGD2–DP1 Axis Regulates Phagocytosis by CD36 + MGs/MΦs That Are Exclusively Present Within Ischemic Areas After Stroke
    Article Snippet: The membranes were incubated with primary antibodies against L-PGDS (1:1000, mouse; Santa Cruz Biotechnology), CD36 (1:2000, goat; R&D Systems), and β-actin (1:2000, mouse; Sigma-Aldrich, St. Louis, MO, USA), followed by incubation with horseradish peroxidase-labeled secondary antibodies (1:2000, mouse; Cell Signaling Technology, Danvers, MA, USA, and 1:1000, goat; Santa Cruz Biotechnology).

    Article Title: L-PGDS–PGD2–DP1 Axis Regulates Phagocytosis by CD36 + MGs/MΦs That Are Exclusively Present Within Ischemic Areas After Stroke
    Article Snippet: The brain tissue sections were deparaffinized and underwent heat treatment using a microwave for epitope retrieval in citrate buffer solution (pH 6.0; Abcam) for 10 min. Then, the samples were incubated with primary antibodies against L-PGDS (1:100, mouse; Santa Cruz Biotechnology, Dallas, TX, USA), glial fibrillary acidic protein (GFAP; 1:1000, rabbit; Abcam), platelet-derived growth factor receptor-β (PDGFRβ; 1:200, goat; R&D Systems, Minneapolis, MN, USA), DP1 (1:200, rabbit; Arigo Biolaboratories Corp., Hsinchu, Taiwan), ionized calcium-binding adapter molecule 1 (Iba1; 1:500, goat; LSBio, Shirley, MA, USA, and 1:500, rabbit; Wako, Osaka, Japan), CD45 (1:200, rat; Thermo Fisher Scientific, Waltham, MA, USA), CD36 (1:100, goat; R&D Systems), and myelin basic protein (MBP; 1:100, mouse; R&D Systems).

    Expressing:

    Article Title: L-PGDS–PGD2–DP1 Axis Regulates Phagocytosis by CD36 + MGs/MΦs That Are Exclusively Present Within Ischemic Areas After Stroke
    Article Snippet: The membranes were incubated with primary antibodies against L-PGDS (1:1000, mouse; Santa Cruz Biotechnology), CD36 (1:2000, goat; R&D Systems), and β-actin (1:2000, mouse; Sigma-Aldrich, St. Louis, MO, USA), followed by incubation with horseradish peroxidase-labeled secondary antibodies (1:2000, mouse; Cell Signaling Technology, Danvers, MA, USA, and 1:1000, goat; Santa Cruz Biotechnology).

    Article Title: L-PGDS–PGD2–DP1 Axis Regulates Phagocytosis by CD36 + MGs/MΦs That Are Exclusively Present Within Ischemic Areas After Stroke
    Article Snippet: The brain tissue sections were deparaffinized and underwent heat treatment using a microwave for epitope retrieval in citrate buffer solution (pH 6.0; Abcam) for 10 min. Then, the samples were incubated with primary antibodies against L-PGDS (1:100, mouse; Santa Cruz Biotechnology, Dallas, TX, USA), glial fibrillary acidic protein (GFAP; 1:1000, rabbit; Abcam), platelet-derived growth factor receptor-β (PDGFRβ; 1:200, goat; R&D Systems, Minneapolis, MN, USA), DP1 (1:200, rabbit; Arigo Biolaboratories Corp., Hsinchu, Taiwan), ionized calcium-binding adapter molecule 1 (Iba1; 1:500, goat; LSBio, Shirley, MA, USA, and 1:500, rabbit; Wako, Osaka, Japan), CD45 (1:200, rat; Thermo Fisher Scientific, Waltham, MA, USA), CD36 (1:100, goat; R&D Systems), and myelin basic protein (MBP; 1:100, mouse; R&D Systems).

    Immunohistochemistry:

    Article Title: L-PGDS–PGD2–DP1 Axis Regulates Phagocytosis by CD36 + MGs/MΦs That Are Exclusively Present Within Ischemic Areas After Stroke
    Article Snippet: The membranes were incubated with primary antibodies against L-PGDS (1:1000, mouse; Santa Cruz Biotechnology), CD36 (1:2000, goat; R&D Systems), and β-actin (1:2000, mouse; Sigma-Aldrich, St. Louis, MO, USA), followed by incubation with horseradish peroxidase-labeled secondary antibodies (1:2000, mouse; Cell Signaling Technology, Danvers, MA, USA, and 1:1000, goat; Santa Cruz Biotechnology).

    Article Title: L-PGDS–PGD2–DP1 Axis Regulates Phagocytosis by CD36 + MGs/MΦs That Are Exclusively Present Within Ischemic Areas After Stroke
    Article Snippet: The brain tissue sections were deparaffinized and underwent heat treatment using a microwave for epitope retrieval in citrate buffer solution (pH 6.0; Abcam) for 10 min. Then, the samples were incubated with primary antibodies against L-PGDS (1:100, mouse; Santa Cruz Biotechnology, Dallas, TX, USA), glial fibrillary acidic protein (GFAP; 1:1000, rabbit; Abcam), platelet-derived growth factor receptor-β (PDGFRβ; 1:200, goat; R&D Systems, Minneapolis, MN, USA), DP1 (1:200, rabbit; Arigo Biolaboratories Corp., Hsinchu, Taiwan), ionized calcium-binding adapter molecule 1 (Iba1; 1:500, goat; LSBio, Shirley, MA, USA, and 1:500, rabbit; Wako, Osaka, Japan), CD45 (1:200, rat; Thermo Fisher Scientific, Waltham, MA, USA), CD36 (1:100, goat; R&D Systems), and myelin basic protein (MBP; 1:100, mouse; R&D Systems).

    Quantitative RT-PCR:

    Article Title: L-PGDS–PGD2–DP1 Axis Regulates Phagocytosis by CD36 + MGs/MΦs That Are Exclusively Present Within Ischemic Areas After Stroke
    Article Snippet: The membranes were incubated with primary antibodies against L-PGDS (1:1000, mouse; Santa Cruz Biotechnology), CD36 (1:2000, goat; R&D Systems), and β-actin (1:2000, mouse; Sigma-Aldrich, St. Louis, MO, USA), followed by incubation with horseradish peroxidase-labeled secondary antibodies (1:2000, mouse; Cell Signaling Technology, Danvers, MA, USA, and 1:1000, goat; Santa Cruz Biotechnology).

    Article Title: L-PGDS–PGD2–DP1 Axis Regulates Phagocytosis by CD36 + MGs/MΦs That Are Exclusively Present Within Ischemic Areas After Stroke
    Article Snippet: The brain tissue sections were deparaffinized and underwent heat treatment using a microwave for epitope retrieval in citrate buffer solution (pH 6.0; Abcam) for 10 min. Then, the samples were incubated with primary antibodies against L-PGDS (1:100, mouse; Santa Cruz Biotechnology, Dallas, TX, USA), glial fibrillary acidic protein (GFAP; 1:1000, rabbit; Abcam), platelet-derived growth factor receptor-β (PDGFRβ; 1:200, goat; R&D Systems, Minneapolis, MN, USA), DP1 (1:200, rabbit; Arigo Biolaboratories Corp., Hsinchu, Taiwan), ionized calcium-binding adapter molecule 1 (Iba1; 1:500, goat; LSBio, Shirley, MA, USA, and 1:500, rabbit; Wako, Osaka, Japan), CD45 (1:200, rat; Thermo Fisher Scientific, Waltham, MA, USA), CD36 (1:100, goat; R&D Systems), and myelin basic protein (MBP; 1:100, mouse; R&D Systems).

    Control:

    Article Title: L-PGDS–PGD2–DP1 Axis Regulates Phagocytosis by CD36 + MGs/MΦs That Are Exclusively Present Within Ischemic Areas After Stroke
    Article Snippet: The membranes were incubated with primary antibodies against L-PGDS (1:1000, mouse; Santa Cruz Biotechnology), CD36 (1:2000, goat; R&D Systems), and β-actin (1:2000, mouse; Sigma-Aldrich, St. Louis, MO, USA), followed by incubation with horseradish peroxidase-labeled secondary antibodies (1:2000, mouse; Cell Signaling Technology, Danvers, MA, USA, and 1:1000, goat; Santa Cruz Biotechnology).

    Article Title: L-PGDS–PGD2–DP1 Axis Regulates Phagocytosis by CD36 + MGs/MΦs That Are Exclusively Present Within Ischemic Areas After Stroke
    Article Snippet: The brain tissue sections were deparaffinized and underwent heat treatment using a microwave for epitope retrieval in citrate buffer solution (pH 6.0; Abcam) for 10 min. Then, the samples were incubated with primary antibodies against L-PGDS (1:100, mouse; Santa Cruz Biotechnology, Dallas, TX, USA), glial fibrillary acidic protein (GFAP; 1:1000, rabbit; Abcam), platelet-derived growth factor receptor-β (PDGFRβ; 1:200, goat; R&D Systems, Minneapolis, MN, USA), DP1 (1:200, rabbit; Arigo Biolaboratories Corp., Hsinchu, Taiwan), ionized calcium-binding adapter molecule 1 (Iba1; 1:500, goat; LSBio, Shirley, MA, USA, and 1:500, rabbit; Wako, Osaka, Japan), CD45 (1:200, rat; Thermo Fisher Scientific, Waltham, MA, USA), CD36 (1:100, goat; R&D Systems), and myelin basic protein (MBP; 1:100, mouse; R&D Systems).

    Derivative Assay:

    Article Title: L-PGDS–PGD2–DP1 Axis Regulates Phagocytosis by CD36 + MGs/MΦs That Are Exclusively Present Within Ischemic Areas After Stroke
    Article Snippet: The membranes were incubated with primary antibodies against L-PGDS (1:1000, mouse; Santa Cruz Biotechnology), CD36 (1:2000, goat; R&D Systems), and β-actin (1:2000, mouse; Sigma-Aldrich, St. Louis, MO, USA), followed by incubation with horseradish peroxidase-labeled secondary antibodies (1:2000, mouse; Cell Signaling Technology, Danvers, MA, USA, and 1:1000, goat; Santa Cruz Biotechnology).

    Article Title: L-PGDS–PGD2–DP1 Axis Regulates Phagocytosis by CD36 + MGs/MΦs That Are Exclusively Present Within Ischemic Areas After Stroke
    Article Snippet: The brain tissue sections were deparaffinized and underwent heat treatment using a microwave for epitope retrieval in citrate buffer solution (pH 6.0; Abcam) for 10 min. Then, the samples were incubated with primary antibodies against L-PGDS (1:100, mouse; Santa Cruz Biotechnology, Dallas, TX, USA), glial fibrillary acidic protein (GFAP; 1:1000, rabbit; Abcam), platelet-derived growth factor receptor-β (PDGFRβ; 1:200, goat; R&D Systems, Minneapolis, MN, USA), DP1 (1:200, rabbit; Arigo Biolaboratories Corp., Hsinchu, Taiwan), ionized calcium-binding adapter molecule 1 (Iba1; 1:500, goat; LSBio, Shirley, MA, USA, and 1:500, rabbit; Wako, Osaka, Japan), CD45 (1:200, rat; Thermo Fisher Scientific, Waltham, MA, USA), CD36 (1:100, goat; R&D Systems), and myelin basic protein (MBP; 1:100, mouse; R&D Systems).

    Reverse Transcription:

    Article Title: L-PGDS–PGD2–DP1 Axis Regulates Phagocytosis by CD36 + MGs/MΦs That Are Exclusively Present Within Ischemic Areas After Stroke
    Article Snippet: The membranes were incubated with primary antibodies against L-PGDS (1:1000, mouse; Santa Cruz Biotechnology), CD36 (1:2000, goat; R&D Systems), and β-actin (1:2000, mouse; Sigma-Aldrich, St. Louis, MO, USA), followed by incubation with horseradish peroxidase-labeled secondary antibodies (1:2000, mouse; Cell Signaling Technology, Danvers, MA, USA, and 1:1000, goat; Santa Cruz Biotechnology).

    Article Title: L-PGDS–PGD2–DP1 Axis Regulates Phagocytosis by CD36 + MGs/MΦs That Are Exclusively Present Within Ischemic Areas After Stroke
    Article Snippet: The brain tissue sections were deparaffinized and underwent heat treatment using a microwave for epitope retrieval in citrate buffer solution (pH 6.0; Abcam) for 10 min. Then, the samples were incubated with primary antibodies against L-PGDS (1:100, mouse; Santa Cruz Biotechnology, Dallas, TX, USA), glial fibrillary acidic protein (GFAP; 1:1000, rabbit; Abcam), platelet-derived growth factor receptor-β (PDGFRβ; 1:200, goat; R&D Systems, Minneapolis, MN, USA), DP1 (1:200, rabbit; Arigo Biolaboratories Corp., Hsinchu, Taiwan), ionized calcium-binding adapter molecule 1 (Iba1; 1:500, goat; LSBio, Shirley, MA, USA, and 1:500, rabbit; Wako, Osaka, Japan), CD45 (1:200, rat; Thermo Fisher Scientific, Waltham, MA, USA), CD36 (1:100, goat; R&D Systems), and myelin basic protein (MBP; 1:100, mouse; R&D Systems).

    Polymerase Chain Reaction:

    Article Title: L-PGDS–PGD2–DP1 Axis Regulates Phagocytosis by CD36 + MGs/MΦs That Are Exclusively Present Within Ischemic Areas After Stroke
    Article Snippet: The membranes were incubated with primary antibodies against L-PGDS (1:1000, mouse; Santa Cruz Biotechnology), CD36 (1:2000, goat; R&D Systems), and β-actin (1:2000, mouse; Sigma-Aldrich, St. Louis, MO, USA), followed by incubation with horseradish peroxidase-labeled secondary antibodies (1:2000, mouse; Cell Signaling Technology, Danvers, MA, USA, and 1:1000, goat; Santa Cruz Biotechnology).

    Article Title: L-PGDS–PGD2–DP1 Axis Regulates Phagocytosis by CD36 + MGs/MΦs That Are Exclusively Present Within Ischemic Areas After Stroke
    Article Snippet: The brain tissue sections were deparaffinized and underwent heat treatment using a microwave for epitope retrieval in citrate buffer solution (pH 6.0; Abcam) for 10 min. Then, the samples were incubated with primary antibodies against L-PGDS (1:100, mouse; Santa Cruz Biotechnology, Dallas, TX, USA), glial fibrillary acidic protein (GFAP; 1:1000, rabbit; Abcam), platelet-derived growth factor receptor-β (PDGFRβ; 1:200, goat; R&D Systems, Minneapolis, MN, USA), DP1 (1:200, rabbit; Arigo Biolaboratories Corp., Hsinchu, Taiwan), ionized calcium-binding adapter molecule 1 (Iba1; 1:500, goat; LSBio, Shirley, MA, USA, and 1:500, rabbit; Wako, Osaka, Japan), CD45 (1:200, rat; Thermo Fisher Scientific, Waltham, MA, USA), CD36 (1:100, goat; R&D Systems), and myelin basic protein (MBP; 1:100, mouse; R&D Systems).

    Western Blot:

    Article Title: L-PGDS–PGD2–DP1 Axis Regulates Phagocytosis by CD36 + MGs/MΦs That Are Exclusively Present Within Ischemic Areas After Stroke
    Article Snippet: The membranes were incubated with primary antibodies against L-PGDS (1:1000, mouse; Santa Cruz Biotechnology), CD36 (1:2000, goat; R&D Systems), and β-actin (1:2000, mouse; Sigma-Aldrich, St. Louis, MO, USA), followed by incubation with horseradish peroxidase-labeled secondary antibodies (1:2000, mouse; Cell Signaling Technology, Danvers, MA, USA, and 1:1000, goat; Santa Cruz Biotechnology).

    Article Title: L-PGDS–PGD2–DP1 Axis Regulates Phagocytosis by CD36 + MGs/MΦs That Are Exclusively Present Within Ischemic Areas After Stroke
    Article Snippet: The brain tissue sections were deparaffinized and underwent heat treatment using a microwave for epitope retrieval in citrate buffer solution (pH 6.0; Abcam) for 10 min. Then, the samples were incubated with primary antibodies against L-PGDS (1:100, mouse; Santa Cruz Biotechnology, Dallas, TX, USA), glial fibrillary acidic protein (GFAP; 1:1000, rabbit; Abcam), platelet-derived growth factor receptor-β (PDGFRβ; 1:200, goat; R&D Systems, Minneapolis, MN, USA), DP1 (1:200, rabbit; Arigo Biolaboratories Corp., Hsinchu, Taiwan), ionized calcium-binding adapter molecule 1 (Iba1; 1:500, goat; LSBio, Shirley, MA, USA, and 1:500, rabbit; Wako, Osaka, Japan), CD45 (1:200, rat; Thermo Fisher Scientific, Waltham, MA, USA), CD36 (1:100, goat; R&D Systems), and myelin basic protein (MBP; 1:100, mouse; R&D Systems).



    Similar Products

    90
    Santa Cruz Biotechnology primary antibodies against l-pgds
    ( A ) <t>L-PGDS</t> expression by WB from samples collected from MCA areas of sham-operated mice or ischemic areas at 1, 3, 5, and 7 days post-stroke. ( B , C ) WB analysis at 7 days post-stroke. L-PGDS expression levels were significantly higher in ischemic areas compared to the contralateral side of nonischemic areas. ( D – G ) Immunohistochemistry for L-PGDS and GFAP. L-PGDS was strongly detected in the leptomeninges of ischemic areas (L-PGDS [( E – G ): red]); GFAP [( E – G ): green]; DAPI [( E – G ): blue]). ( H – K ) Immunohistochemistry for L-PGDS and PDGFRβ. L-PGDS was co-expressed in PDGFRβ + pericytes in the leptomeninges of ischemic areas (( I – K ), arrows) (L-PGDS [( I , J ): red]; PDGFRβ [( I , K ): green]; DAPI [( I – K ): blue]). ( L – N ) RT-qPCR analysis. L-PGDS levels were significantly higher in brain pericytes treated with supernatant from ischemic areas ( M , N ) than in untreated pericytes (control) ( L , N ). Scale bars: ( E – G ) 100 µm; ( I ) 20 µm. * p < 0.05 between the contralateral side of nonischemic areas and ischemic areas, n = 3 for each area ( C ). * p < 0.05 between the control and supernatant–treated group, n = 3 for each group ( N ). Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; GFAP, glial fibrillary acidic protein; L-PGDS, lipocalin-type prostaglandin D synthase; MCA, middle cerebral artery; PDGFRβ, platelet-derived growth factor receptor-β; RT-qPCR, quantitative reverse transcription-polymerase chain reaction; WB, Western blot.
    Primary Antibodies Against L Pgds, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibodies+against+l-pgds/primary+antibodies+against+l+pgds/pmc11505914-66-6-11
    Average 90 stars, based on 1 article reviews
    primary antibodies against l-pgds - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    Cayman Chemical primary antibodies against cox-2 and lipocalin-type pgd synthase (l-pgds)
    ( A ) <t>L-PGDS</t> expression by WB from samples collected from MCA areas of sham-operated mice or ischemic areas at 1, 3, 5, and 7 days post-stroke. ( B , C ) WB analysis at 7 days post-stroke. L-PGDS expression levels were significantly higher in ischemic areas compared to the contralateral side of nonischemic areas. ( D – G ) Immunohistochemistry for L-PGDS and GFAP. L-PGDS was strongly detected in the leptomeninges of ischemic areas (L-PGDS [( E – G ): red]); GFAP [( E – G ): green]; DAPI [( E – G ): blue]). ( H – K ) Immunohistochemistry for L-PGDS and PDGFRβ. L-PGDS was co-expressed in PDGFRβ + pericytes in the leptomeninges of ischemic areas (( I – K ), arrows) (L-PGDS [( I , J ): red]; PDGFRβ [( I , K ): green]; DAPI [( I – K ): blue]). ( L – N ) RT-qPCR analysis. L-PGDS levels were significantly higher in brain pericytes treated with supernatant from ischemic areas ( M , N ) than in untreated pericytes (control) ( L , N ). Scale bars: ( E – G ) 100 µm; ( I ) 20 µm. * p < 0.05 between the contralateral side of nonischemic areas and ischemic areas, n = 3 for each area ( C ). * p < 0.05 between the control and supernatant–treated group, n = 3 for each group ( N ). Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; GFAP, glial fibrillary acidic protein; L-PGDS, lipocalin-type prostaglandin D synthase; MCA, middle cerebral artery; PDGFRβ, platelet-derived growth factor receptor-β; RT-qPCR, quantitative reverse transcription-polymerase chain reaction; WB, Western blot.
    Primary Antibodies Against Cox 2 And Lipocalin Type Pgd Synthase (L Pgds), supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibodies+against+l-pgds/cox+2+antibody/pmc04290712-67-21-29
    Average 90 stars, based on 1 article reviews
    primary antibodies against cox-2 and lipocalin-type pgd synthase (l-pgds) - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    Image Search Results


    ( A ) L-PGDS expression by WB from samples collected from MCA areas of sham-operated mice or ischemic areas at 1, 3, 5, and 7 days post-stroke. ( B , C ) WB analysis at 7 days post-stroke. L-PGDS expression levels were significantly higher in ischemic areas compared to the contralateral side of nonischemic areas. ( D – G ) Immunohistochemistry for L-PGDS and GFAP. L-PGDS was strongly detected in the leptomeninges of ischemic areas (L-PGDS [( E – G ): red]); GFAP [( E – G ): green]; DAPI [( E – G ): blue]). ( H – K ) Immunohistochemistry for L-PGDS and PDGFRβ. L-PGDS was co-expressed in PDGFRβ + pericytes in the leptomeninges of ischemic areas (( I – K ), arrows) (L-PGDS [( I , J ): red]; PDGFRβ [( I , K ): green]; DAPI [( I – K ): blue]). ( L – N ) RT-qPCR analysis. L-PGDS levels were significantly higher in brain pericytes treated with supernatant from ischemic areas ( M , N ) than in untreated pericytes (control) ( L , N ). Scale bars: ( E – G ) 100 µm; ( I ) 20 µm. * p < 0.05 between the contralateral side of nonischemic areas and ischemic areas, n = 3 for each area ( C ). * p < 0.05 between the control and supernatant–treated group, n = 3 for each group ( N ). Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; GFAP, glial fibrillary acidic protein; L-PGDS, lipocalin-type prostaglandin D synthase; MCA, middle cerebral artery; PDGFRβ, platelet-derived growth factor receptor-β; RT-qPCR, quantitative reverse transcription-polymerase chain reaction; WB, Western blot.

    Journal: Cells

    Article Title: L-PGDS–PGD2–DP1 Axis Regulates Phagocytosis by CD36 + MGs/MΦs That Are Exclusively Present Within Ischemic Areas After Stroke

    doi: 10.3390/cells13201737

    Figure Lengend Snippet: ( A ) L-PGDS expression by WB from samples collected from MCA areas of sham-operated mice or ischemic areas at 1, 3, 5, and 7 days post-stroke. ( B , C ) WB analysis at 7 days post-stroke. L-PGDS expression levels were significantly higher in ischemic areas compared to the contralateral side of nonischemic areas. ( D – G ) Immunohistochemistry for L-PGDS and GFAP. L-PGDS was strongly detected in the leptomeninges of ischemic areas (L-PGDS [( E – G ): red]); GFAP [( E – G ): green]; DAPI [( E – G ): blue]). ( H – K ) Immunohistochemistry for L-PGDS and PDGFRβ. L-PGDS was co-expressed in PDGFRβ + pericytes in the leptomeninges of ischemic areas (( I – K ), arrows) (L-PGDS [( I , J ): red]; PDGFRβ [( I , K ): green]; DAPI [( I – K ): blue]). ( L – N ) RT-qPCR analysis. L-PGDS levels were significantly higher in brain pericytes treated with supernatant from ischemic areas ( M , N ) than in untreated pericytes (control) ( L , N ). Scale bars: ( E – G ) 100 µm; ( I ) 20 µm. * p < 0.05 between the contralateral side of nonischemic areas and ischemic areas, n = 3 for each area ( C ). * p < 0.05 between the control and supernatant–treated group, n = 3 for each group ( N ). Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; GFAP, glial fibrillary acidic protein; L-PGDS, lipocalin-type prostaglandin D synthase; MCA, middle cerebral artery; PDGFRβ, platelet-derived growth factor receptor-β; RT-qPCR, quantitative reverse transcription-polymerase chain reaction; WB, Western blot.

    Article Snippet: The membranes were incubated with primary antibodies against L-PGDS (1:1000, mouse; Santa Cruz Biotechnology), CD36 (1:2000, goat; R&D Systems), and β-actin (1:2000, mouse; Sigma-Aldrich, St. Louis, MO, USA), followed by incubation with horseradish peroxidase-labeled secondary antibodies (1:2000, mouse; Cell Signaling Technology, Danvers, MA, USA, and 1:1000, goat; Santa Cruz Biotechnology).

    Techniques: Expressing, Immunohistochemistry, Quantitative RT-PCR, Control, Derivative Assay, Reverse Transcription, Polymerase Chain Reaction, Western Blot